The growth in the historic period can be attributed to availability of plasma fractionation technologies, increased awareness of varicella complications, expansion of hospital-based prophylaxis protocols, regulatory approvals for hyperimmune globulins, established immunization infrastructure.
The growth in the forecast period can be attributed to growing demand for immunocompromised patient protection, increasing focus on maternal and neonatal care, expansion of plasma collection networks, advancements in biologic safety screening, rising investment in preventive immunotherapies. Major trends in the forecast period include increasing use of passive immunization therapies, growing focus on high-risk patient protection, expansion of plasma-derived biologic products, rising emphasis on post-exposure prophylaxis, enhanced cold-chain management practices.
The rising incidence of varicella-zoster virus infections is expected to propel the growth of the varizig market in the coming years. The varicella-zoster virus (VZV) is a highly contagious virus that initially causes chickenpox and can reactivate later in life to cause shingles (herpes zoster). The increase in varicella-zoster virus (VZV) infections, resulting in conditions such as chickenpox and shingles, is linked to declining vaccination rates, an aging population, and immune suppression from medical treatments. Varizig supports varicella-zoster virus patients by providing passive immunity, lessening the severity and duration of chickenpox symptoms, preventing complications in high-risk individuals such as immunocompromised patients, and offering protection against severe outcomes in neonates and pregnant women exposed to the virus. For example, in November 2024, according to the Florida Department of Health, a US government agency, varicella cases rose to 653 in 2023, compared to 428 cases in 2022. Consequently, the growing incidence of varicella-zoster virus infections drives the varizig market.
The increase in healthcare spending is expected to drive the growth of the varizig market in the coming years. Healthcare spending refers to the total outlay on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, aimed at maintaining or improving the health and well-being of individuals and populations. Healthcare spending is influenced by factors such as an aging population, advancements in medical technology, rising prevalence of chronic diseases, and growing demand for healthcare services. Healthcare expenditure supports varizig by providing funding for the procurement and distribution of this critical immune globulin, ensuring its accessibility to high-risk populations, enabling healthcare providers to deliver timely treatment for varicella-zoster virus infections, and helping to reduce the overall healthcare burden associated with severe complications from the virus. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare spending in the UK increased by 5.6% between 2022 and 2023 compared with a growth of 0.9% in 2022. The UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending is fueling the growth of the varizig market.
Major companies operating in the VariZIG market are emphasizing technological advancements through manufacturing scale-up and enhanced distribution logistics, including contract manufacturing optimization, regional supply-chain agreements, and cold-chain/stability improvements that ensure timely delivery of plasma-derived immunoglobulins to populations with high medical need. Manufacturing scale-up and distribution logistics encompass a set of process and infrastructure innovations such as increased production capacity, robust cold-chain and inventory management, regional supply agreements, and coordinated procurement contracts that transform limited specialist biologic products from niche availability into consistently accessible therapies across regions. For example, in January 2025, Kamada Ltd., an Israel-based biopharmaceutical company specializing in plasma-derived therapies, announced a $25 million three-year contract to supply KAMRAB and VARIZIG across Latin America from 2025 through 2027. This agreement secures regional supply and mitigates the risk of shortages for at-risk patients, allowing hospitals and public health systems to plan prophylaxis and treatment with greater certainty. It also broadens commercial access to a previously fragmented market by establishing predictable demand and distribution channels across multiple countries, supporting faster patient access. Finally, the contract strengthens public-health preparedness for varicella exposure in high-risk groups by ensuring a reliable supply pathway for an essential passive-immunity product.
Major companies operating in the varizig market are Emergent BioSolutions Inc.
North America was the largest region in the varizig market in 2025. The regions covered in the varizig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the varizig market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the varizig market by increasing costs of imported plasma derivatives, fractionation equipment, sterile packaging materials, and temperature-controlled logistics services. North America and Europe are most affected due to reliance on global plasma supply chains, while Asia-Pacific faces higher import costs for specialty immunoglobulins. These tariffs raise procurement costs for healthcare providers. However, they also encourage regional plasma processing investments and strengthen domestic biologics manufacturing resilience.
The varizig market research report is one of a series of new reports that provides varizig market statistics, including varizig industry global market size, regional shares, competitors with a varizig market share, detailed varizig market segments, market trends and opportunities, and any further data you may need to thrive in the varizig industry. This varizig market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
VariZIG is a hyperimmune globulin obtained from human plasma that contains high levels of antibodies against the varicella-zoster virus (VZV). It is used as post-exposure prophylaxis to lessen the severity of chickenpox in high-risk individuals, including immunocompromised patients, pregnant women, and newborns. Administered intramuscularly, it provides passive immunity by supplying pre-formed antibodies. Varizig is most effective when administered within 96 hours of VZV exposure.
The primary patient groups for Varizig are immunocompromised individuals and pregnant women. Immunocompromised patients have weakened immune systems due to conditions such as HIV, cancer treatments, or immunosuppressive therapy. These are supplied through multiple distribution channels including hospitals, pharmacies, and healthcare providers and are utilized by various end users such as adults, geriatric, and pediatric populations.
The varizig market consists of sales of pre-filled syringes, injectable solutions, and single-dose vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to growing demand for immunocompromised patient protection, increasing focus on maternal and neonatal care, expansion of plasma collection networks, advancements in biologic safety screening, rising investment in preventive immunotherapies. Major trends in the forecast period include increasing use of passive immunization therapies, growing focus on high-risk patient protection, expansion of plasma-derived biologic products, rising emphasis on post-exposure prophylaxis, enhanced cold-chain management practices.
The rising incidence of varicella-zoster virus infections is expected to propel the growth of the varizig market in the coming years. The varicella-zoster virus (VZV) is a highly contagious virus that initially causes chickenpox and can reactivate later in life to cause shingles (herpes zoster). The increase in varicella-zoster virus (VZV) infections, resulting in conditions such as chickenpox and shingles, is linked to declining vaccination rates, an aging population, and immune suppression from medical treatments. Varizig supports varicella-zoster virus patients by providing passive immunity, lessening the severity and duration of chickenpox symptoms, preventing complications in high-risk individuals such as immunocompromised patients, and offering protection against severe outcomes in neonates and pregnant women exposed to the virus. For example, in November 2024, according to the Florida Department of Health, a US government agency, varicella cases rose to 653 in 2023, compared to 428 cases in 2022. Consequently, the growing incidence of varicella-zoster virus infections drives the varizig market.
The increase in healthcare spending is expected to drive the growth of the varizig market in the coming years. Healthcare spending refers to the total outlay on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, aimed at maintaining or improving the health and well-being of individuals and populations. Healthcare spending is influenced by factors such as an aging population, advancements in medical technology, rising prevalence of chronic diseases, and growing demand for healthcare services. Healthcare expenditure supports varizig by providing funding for the procurement and distribution of this critical immune globulin, ensuring its accessibility to high-risk populations, enabling healthcare providers to deliver timely treatment for varicella-zoster virus infections, and helping to reduce the overall healthcare burden associated with severe complications from the virus. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare spending in the UK increased by 5.6% between 2022 and 2023 compared with a growth of 0.9% in 2022. The UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending is fueling the growth of the varizig market.
Major companies operating in the VariZIG market are emphasizing technological advancements through manufacturing scale-up and enhanced distribution logistics, including contract manufacturing optimization, regional supply-chain agreements, and cold-chain/stability improvements that ensure timely delivery of plasma-derived immunoglobulins to populations with high medical need. Manufacturing scale-up and distribution logistics encompass a set of process and infrastructure innovations such as increased production capacity, robust cold-chain and inventory management, regional supply agreements, and coordinated procurement contracts that transform limited specialist biologic products from niche availability into consistently accessible therapies across regions. For example, in January 2025, Kamada Ltd., an Israel-based biopharmaceutical company specializing in plasma-derived therapies, announced a $25 million three-year contract to supply KAMRAB and VARIZIG across Latin America from 2025 through 2027. This agreement secures regional supply and mitigates the risk of shortages for at-risk patients, allowing hospitals and public health systems to plan prophylaxis and treatment with greater certainty. It also broadens commercial access to a previously fragmented market by establishing predictable demand and distribution channels across multiple countries, supporting faster patient access. Finally, the contract strengthens public-health preparedness for varicella exposure in high-risk groups by ensuring a reliable supply pathway for an essential passive-immunity product.
Major companies operating in the varizig market are Emergent BioSolutions Inc.
North America was the largest region in the varizig market in 2025. The regions covered in the varizig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the varizig market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the varizig market by increasing costs of imported plasma derivatives, fractionation equipment, sterile packaging materials, and temperature-controlled logistics services. North America and Europe are most affected due to reliance on global plasma supply chains, while Asia-Pacific faces higher import costs for specialty immunoglobulins. These tariffs raise procurement costs for healthcare providers. However, they also encourage regional plasma processing investments and strengthen domestic biologics manufacturing resilience.
The varizig market research report is one of a series of new reports that provides varizig market statistics, including varizig industry global market size, regional shares, competitors with a varizig market share, detailed varizig market segments, market trends and opportunities, and any further data you may need to thrive in the varizig industry. This varizig market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
VariZIG is a hyperimmune globulin obtained from human plasma that contains high levels of antibodies against the varicella-zoster virus (VZV). It is used as post-exposure prophylaxis to lessen the severity of chickenpox in high-risk individuals, including immunocompromised patients, pregnant women, and newborns. Administered intramuscularly, it provides passive immunity by supplying pre-formed antibodies. Varizig is most effective when administered within 96 hours of VZV exposure.
The primary patient groups for Varizig are immunocompromised individuals and pregnant women. Immunocompromised patients have weakened immune systems due to conditions such as HIV, cancer treatments, or immunosuppressive therapy. These are supplied through multiple distribution channels including hospitals, pharmacies, and healthcare providers and are utilized by various end users such as adults, geriatric, and pediatric populations.
The varizig market consists of sales of pre-filled syringes, injectable solutions, and single-dose vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. VariZIG Market Characteristics
3. VariZIG Market Supply Chain Analysis
4. Global VariZIG Market Trends and Strategies
5. VariZIG Market Analysis of End Use Industries
7. Global VariZIG Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global VariZIG Total Addressable Market (TAM) Analysis for the Market
9. VariZIG Market Segmentation
10. VariZIG Market Regional and Country Analysis
11. Asia-Pacific VariZIG Market
12. China VariZIG Market
13. India VariZIG Market
14. Japan VariZIG Market
15. Australia VariZIG Market
16. South Korea VariZIG Market
17. Western Europe VariZIG Market
18. UK VariZIG Market
19. Germany VariZIG Market
20. France VariZIG Market
21. Eastern Europe VariZIG Market
22. North America VariZIG Market
23. USA VariZIG Market
24. Canada VariZIG Market
25. South America VariZIG Market
26. Middle East VariZIG Market
27. Africa VariZIG Market
29. VariZIG Market Competitive Landscape and Company Profiles
32. VariZIG Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
VariZIG Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses varizig market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for varizig? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The varizig market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Patient Condition: Immunocompromised Patients; Pregnant Women2) By Distribution Channel: Hospitals; Pharmacies; Healthcare Providers
3) By End User: Adult; Geriatric; Pediatric
Companies Mentioned: Emergent BioSolutions Inc.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this VariZIG market report include:- Emergent BioSolutions Inc.
